(Q37889298)

24 August 2017

1 reference

title

Drug safety evaluation of adefovir in HBV infection (English)

1 reference

24 August 2017

Mauro Viganò

1

1 reference

24 August 2017

Pietro Lampertico

series ordinal

2

1 reference

24 August 2017

Massimo Colombo

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

15 June 2011

1 reference

Expert Opinion on Drug Safety

24 August 2017

published in

1 reference

24 August 2017

volume

10

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

809-818

1 reference

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Side effects of long-term oral antiviral therapy for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Adefovir dipivoxil: a review of its use in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Antiviral drug-induced nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Hepatic gene expression and prediction of therapy response in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Adefovir dipivoxil-induced acute tubular necrosis and Fanconi syndrome in a renal transplant patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Fanconi's Syndrome Associated with Prolonged Adefovir Dipivoxil Therapy in a Hepatitis B Virus Patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Hypophosphataemic osteomalacia in patients on adefovir dipivoxil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

Adefovir dipivoxil for wait-listed and post–liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.593507

10.1517/14740338.2011.593507

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference